Pasithea Therapeutics Welcomes Dr. Rebecca Brown to Advisory Board
MIAMI, Sept. 03, 2024 -- Pasithea Therapeutics Corp. (NASDAQ: KTTA), a biotechnology company currently in clinical stages, has announced that Dr. Rebecca Brown, M.D., Ph.D., will join its Scientific Advisory Board. This appointment underscores the company’s dedication to advancing its innovative therapy, PAS-004, which targets neurofibromatosis type 1 (NF1) and related conditions.
Dr. Rebecca Brown's Expertise in Neurofibromatosis
Dr. Brown is the Director of the Neurofibromatosis Clinic at The Mount Sinai Hospital and serves as an Assistant Professor in the Division of Neuro-Oncology within the Department of Neurology. Her extensive knowledge and clinical background in NF1 will provide invaluable insights to Pasithea as it moves forward with PAS-004.
Significant Contributions to NF1 Research
Dr. Brown has a rich history as an investigator in various NF1 research initiatives, focusing particularly on cutaneous and plexiform neurofibromas. She boasts a strong publication record in prestigious scientific journals and frequently shares her insights at both national and international conferences.
Comments from Leadership
“We are thrilled to welcome Dr. Brown, a globally recognized expert in NF1, to our Scientific Advisory Board,” said Dr. Tiago Reis Marques, CEO of Pasithea. Dr. Brown’s expertise will be instrumental in the upcoming Phase 1/2a clinical trial for PAS-004, further enhancing the company’s development strategy.
Dr. Brown's Vision for PAS-004
Expressing her enthusiasm for her new role, Dr. Brown stated, “I am eager to contribute to the development of PAS-004, a next-generation macrocyclic MEK inhibitor that shows promising preclinical data for NF1. This treatment has the potential to address significant unmet medical needs and is distinguished from similar drugs due to its unique profile.”
A Closer Look at PAS-004
PAS-004 is identified as a small molecule allosteric inhibitor of MEK 1/2 within the MAPK signaling pathway. Abnormal activation of this pathway can lead to cancer cell proliferation and contribute to various diseases, including NF1. By inhibiting MEK, PAS-004 aims to trigger cell death and restrict tumor growth, overcoming the limitations of existing FDA-approved MEK inhibitors.
Potential Benefits of PAS-004
One of the key advantages of PAS-004 is its macrocyclic structure, which may enhance pharmacokinetic properties and improve safety profiles. Designed to provide a longer half-life and greater dosing flexibility, the compound aims to ensure effective treatment while promoting patient compliance.
The Role of Pasithea Therapeutics
Pasithea is committed to researching and developing cutting-edge therapies for central nervous system disorders and genetic syndromes such as RASopathies. Supported by a skilled team of professionals, the company aims to create innovative molecules targeting neurological diseases, including NF1, solid tumors, and amyotrophic lateral sclerosis (ALS).
Frequently Asked Questions
What is Pasithea Therapeutics focused on?
Pasithea Therapeutics is dedicated to developing innovative treatments for central nervous system disorders and genetic syndromes.
Who is Dr. Rebecca Brown?
Dr. Rebecca Brown is a board-certified adult neuro-oncologist specializing in Neurofibromatosis, and she has been appointed to the Scientific Advisory Board of Pasithea.
What is PAS-004?
PAS-004 is a macrocyclic MEK inhibitor that aims to treat neurofibromatosis type 1 while potentially enhancing treatment efficacy and patient compliance.
How does PAS-004 differ from current treatments?
PAS-004 seeks to offer a better safety profile and therapeutic window compared to existing MEK inhibitors, which may improve overall treatment outcomes.
What are the upcoming plans for Pasithea?
Pasithea plans to initiate a Phase 1/2a clinical trial for PAS-004 as part of its ongoing drug development initiatives.
